Press Releases

April 10, 2019 Devonian Health Group Announces the Formation of a Scientific Advisory Board with mandate to assist in the development of Cannabinoïds-based pharmaceutical products

April 08, 2019 Devonian Health Group announces the publication of results of in vitro assessment of the antioxidant and UV protection properties of thylakoid extracts in Journal of Cosmetic Dermatology

April 02, 2019 Devonian Healthcare Group Reports Key Financial Results for Quarter Ended January 31, 2019

April 01, 2019 Devonian Health Group issues Securities In Interest Settlement Due To Debenture Holders and grants options

January 31, 2019 Devonian Announces voting results of the Annual General and Special Meeting

January 29, 2019 Devonian Health Group Provides an update on its Phase 2 Clinical Study in Atopic Dermatitis and Announces plans for the first photoprotection product issued from its Cosmeceutical R&D program

January 23, 2019 Devonian Health Group Announces the refinancing of the loan on its pharmaceutical facility

December 20, 2018 Devonian Health Group Announces 2018 Annual General Shareholder’s Meeting

November 12, 2018 Devonian Health Group announces the recognition of Sybil Dahan, President of Altius Healthcare, as inductee into the 2018 Canadian Healthcare Marketing Hall of Fame.

October 03, 2018 Devonian Health Group Receives 2018 Best Anti-Aging Skin Treatment Technology from LUX Life Magazine.

September 04, 2018 Devonian Health Group announces the completion of the second tranche of its previously announced private placement and provides an update.

August 08, 2018 Devonian Health Group provides an update on its previously announced private placement.

July 31, 2018 Devonian Health Group Announces issuance of European Patent for its Purgenesis™ anti-aging treatment.

July 19, 2018 Devonian Health Group announces Non-Brokered Financing by way of a private placement of Convertible Debenture.

July 18, 2018 Devonian Healthcare Group Reports its First ever Revenues: Key Financial Results for Quarter Ended April 30th, 2018

June 29, 2018 Devonian Announces Grant of Options

June 28, 2018 Devonian Announces the Signing of a Non-Binding Letter of Intent with Folia Biotech to develop FB-631 in cancer immunotherapy.

June 27, 2018 Devonian Health Group Announces issuance of United States Patent for its Purgenesis™ anti-aging treatment.

June 26, 2018 Devonian Health Group announces the commercial launch of the Purgenesis™ Anti-aging treatment at the Canadian Dermatology Association’s annual conference

June 07, 2018 Purgenesis™: Commercializing a Skin-Care Revolution

May 16, 2018 Devonian Health Group Announces Canadian Patent for its Purgenesis™ anti-aging treatment

March 20, 2018 Devonian Announces Grant of Options

February 26, 2018 Devonian announces the trading of its shares will resume on Tuesday February 27th, 2018

February 12, 2018 Aspri Pharma Canada Inc. Announces Acquisition of Subordinate Voting Shares of Devonian Health Group Inc.

February 01, 2018 Devonian Announces Acquisition of Altius Healthcare

January 15, 2018 Devonian Announces voting results of the Annual General and Special Meeting

November 16, 2017 Devonian Announces the Filing of New Patent Application for ThykamineTM

November 09, 2017 Devonian Announces Initiation of Phase IIa Clinical Trial of ThykamineTM in Adult patients with Mild-to-Moderate Atopic Dermatitis

September 28, 2017 Devonian Health Announces PurgenesisTM anti-aging treatment marketing and distribution partnership.

September 14, 2017 Devonian Health Group to present at GCFF (Global Chinese Financial Conference) 18th annual conference

September 06, 2017 Devonian Health Group’s Purgenesis™ anti-aging derma-cosmeceutical treatment is now recognized through the Canadian Dermatology Association Skin Health Program

July 13, 2017 DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES CLOSING OF PRIVATE PLACEMENT

July 07, 2017 DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES GRANT OF OPTIONS

June 22, 2017 DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES PLANS FOR ITS DERMATOLOGY PROGRAM OF THYKAMINE

June 21, 2017 DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES ISSUANCE OF ONE NEW KEY PATENT AND THE GRANTING OF A TRADEMARK

May 31, 2017 DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE BOARD OF DIRECTORS AND SENIOR MANAGEMENT CHANGES TO SUPPORT GROWTH STRATEGY

May 18, 2017 DEVONIAN HEALTH GROUP INC.- LISTING OF ITS SHARES ON THE TSX VENTURE EXCHANGE

May 15, 2017 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC.- COMPLETION OF THE AMALGAMATION AND CLOSING OF A CONCURENT PUBLIC OFFERING

April 27, 2017 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – END OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING

February 03, 2017 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – RECEIPT FOR ITS AMENDED AND RESTATED PROSPECTUS

November 25, 2016 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – RESULTS OF THE VOTES FROM THE ANNUAL GENERAL MEETING OF ORLETTO

November 09, 2016 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – RESULTS OF THE VOTES FROM THE ANNUAL GENERAL MEETING OF DEVONIAN

November 07, 2016 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – DEVONIAN APPOINTS DR JEAN-CLAUDE TARDIF AS CHAIRMAN OF SCIENTIFIC ADVISORY BOARD

August 23, 2016 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – FINANCING BY WAY OF LONG FORM PROSPECTUS

April 26, 2016 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – AGREEMENT IN PRINCIPLE

May 20, 2015 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – AGREEMENT IN PRINCIPLE